Skip to main content

Table 2 Summary of efficacy and tolerability data

From: S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review

Study SAMe sample Control sample MD SAMe MD control Efficacy Side effects Response method Response rate SAMe Response rate control
Caruso 1984 [36] 25 24 11.4 (7.7) 2.9 (6.4) SAMe better than placebo Not reported NR NR NR
Kagan 1990 [37] 9 6 16.2 (6.9) 7.3 (14.3) SAMe better than placebo Mild side effects only, resolved spontaneously NR NR NR
Berlanga 1992 [38] 20 20 13.7 (4.6) 9.6 (6.2) SAMe + IMI better than placebo + IMI Typical anticholinergic effects of IMI (mild). Mild weight gain Reduction
HAM ≥ 50%
65 45
Papakostas 2010 [39] * 24 31 11.1 (6.1) 15.8 (6.2) SAMe + SRI better than placebo + SRI Slightly higher mean supine systolic blood pressure in the treatment group Reduction
HAM ≥ 50%
75.0 12.9
Delle Chiaie 2002a [40] 143 135 12.6 (8.1) 13.1 (8.6) SAMe equal to imipramine Dry mouth, constipation, and tachycardia. More frequent IMI Reduction
HAM ≥ 50%
51 57
Delle Chiaie 2002b [40] 146 147 12.6 (8.0) 13.1 (7.1) SAMe equal to imipramine Reduction
HAM ≥ 50%
58.9 50.3
Mischoulon 2014a [41] 36 31 6.19 (7.38) 5.11 (6.92) SAMe equal to placebo Good tolerability. GI complaints Reduction
HAM ≥ 50%
35 30
Mischoulon 2014b [41] 36 30 6.19 (7.38) 6.31 (6.98) SAMe equal to escitalopram Reduction
HAM ≥ 50%
35 34
Sarris 2014a [42] 18 16 7.31 (5.96) 4.0 (5.6) SAMe better than placebo Interventions were well tolerated with no significant adverse effects Reduction
HAM ≥ 50%
45 26
Sarris 2014b [42] 18 20 7.31 (5.96) 6.69 (5.7) SAMe equal to escitalopram Reduction
HAM ≥ 50%
45 31
Sarris 2018 [43] 37 39 11.4 (7.54) 12.1 (7.02) SAMe equal to placebo Irritability, hot/cold flashes, cramping, confusion, headache, vertigo/dizziness, twitching, sleep difficulty and fatigue Reduction MADRS ≥ 50% 54.3 50
  1. NR not reported, MD mean difference